drug_type
RELEVANT_DRUG
intervention_type
Small-molecule tyrosine kinase inhibitor (TKI)
drug_description
Second-generation irreversible pan-HER EGFR-family inhibitor.
nci_thesaurus_concept_id
C53398
nci_thesaurus_preferred_term
Dacomitinib
nci_thesaurus_definition
A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors.
drug_mesh_term
dacomitinib
drug_category
SMALL MOLECULE DRUG
drug_class
Inhibitor
drug_delivery_route
Oral
drug_mechanism_of_action
Second‑generation, irreversible pan‑HER tyrosine kinase inhibitor that covalently inhibits EGFR (HER1), HER2, and HER4, blocking downstream signaling (e.g., MAPK/PI3K‑AKT) to suppress proliferation and induce apoptosis in tumors driven by these receptors.
drug_name
dacomitinib
nct_id_drug_ref
NCT05834348